您好，欢迎来到化工原料网！ [登录] [免费注册]
化工原料网
发布求购
位置：首页 > 产品库 > Levosimendan
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Levosimendan
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Levosimendan图片
CAS NO:141505-33-1
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议

产品介绍
左西孟旦 (Simsndan; OR-1259) 是一种钙增敏剂，用于治疗急性失代偿性充血性心力衰竭。
Cas No.141505-33-1
别名左西孟旦; Simsndan; OR-1259
化学名2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
Canonical SMILESCC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
分子式C14H12N6O
分子量280.28
溶解度≥ 9.75mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy[1]. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators[2]. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients[3].

References:
[1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245.
[2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7.
[3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.